

Color Data Listings and Color Patient Profiles

Charley Z. Wu, Atara Biotherapeutics

1 ABSTRACT:

During clinical trials, there are frequent datacuts for safety data review, interim data analysis, CSRs. Data reviewers usually need to review the data carefully to ensure data accuracy and integrity. They frequently complain that they have already reviewed the same data many times before, and they don't like to review the same data again. They would rather pay more attention to new and updated data. However, most of data listings/patient profiles/reports cannot tell what are new data and what are old data.

To solve this issue, we developed color data listings and color patient profiles. The idea is that we can set the first datacut as a benchmark, all future data changes are then highlighted with different colors. For example, updated data are colored pink. New data are colored green. Deleted data are colored grey. Unchanged data are not colored. By doing so, reviewers can easily identify any data changes since previous datacut.

Though we just implemented this in regular data listings and patient profiles, we already got very positive feedback from data reviewers. It usually takes them 1-2 weeks to finish the review of all data listings and patient profiles. They can now finish data review in a couple of days. It also makes data review an enjoyable process as colored data changes pop up to reviewer's eyes.

2. INTRODUCTION:

In the life cycle of clinical trials, there are frequent datacuts for safety data review, interim data analysis, conference presentations, CSRs, etc. Medical Monitors, Statisticians, Clinical Data Managers, Pharmacovigilance will need to review the data carefully to ensure data accuracy and integrity. These functions frequently complain that they have already reviewed the same data many times before, and they don't like to review the same data repeatedly. They prefer to see new and updated data only. However, most of data listings/patient profiles/reports cannot tell what are new data and what are old data.

To solve this issue, we developed color data listings and color patient profiles. The idea is that we can set the first datacut as benchmark, all future data changes are then highlighted with different colors. For example, update data are colored pink. New data are colored green. Deleted data are colored grey. Unchanged data are not colored. By doing so, reviewers can easily identify any new, updated, or deleted data since last datacut.

3. FOLDER AND DATA STRUCTURE SETUP

In order to produce color data listings correctly and robustly, proper data and folder structures should be setup first.

- **Benchmark folder:** This is the initial folder that future data will be compared to. This is usually the first datacut of a study which has all SAS datasets. It can be anywhere on the SAS server. For example:

F:\Project1\Study999_100\Datasets\Snapshots\20180312\

- **Current folder:** This is for current SAS datasets that will be compared with benchmark folder above. For example:
F:\Project1\Study999_100\Datasets\Current\
- **Output folder:** This is the where color data listings will be created. They can be in PDF, XLS, or RTF formats. For example:
F:\Project1\Study999_100\Output\Color_Listings\
- **SAS program folder:** This is where SAS programs reside.
- **Temp SAS dataset folder:** In order to produce color data listings, a lot of data processing is required. During the process, many temp datasets are created. We keep two set of datasets produced for color listings.
 - **Compare Folder:** This folder has the final datasets which will produce color data listings. For example:
F:\Project1\Study999_100\Datasets\Compare\

The **data structure** of these datasets is identical to that of source datasets with one additional variable **Benchmark**. This **Benchmark** variable identifies whether a record is new, updated, or deleted. For example:

| | A | B | U | X | Y | AB | AC | |
|-----|-------------------------------------|---------|-------------|-------------|----------------------------|----------------|--------------|---|
| 1 | Benchmark | Subject | Start Date | End Date | Outcome | Action Taken | Relationship | |
| 69 | | AAAAA | 25 Mar 2019 | 30 Mar 2019 | Recovered/resolved | Not Applicable | Unrelated | 0 |
| 70 | Updated after snapshot on 07OCT2019 | AAAAA | 17 Jul 2019 | | Not recovered/not resolved | Not Applicable | Unrelated | 1 |
| 90 | Updated after snapshot on 07OCT2019 | CCCCC | 03 Sep 2019 | 03 Oct 2019 | Recovered/resolved | Not Applicable | Unrelated | 1 |
| 102 | Deleted after snapshot on 07OCT2019 | DDDDD | 28 Feb 2019 | | Not recovered/not resolved | Not Applicable | Unrelated | 0 |
| 105 | New after snapshot on 07OCT2019 | EEEEEE | 12 Oct 2019 | 7 Nov 2019 | Recovered/resolved | Not Applicable | Unrelated | 1 |
| 106 | New after snapshot on 07OCT2019 | EEEEEE | 1 Oct 2019 | 8 Oct 2019 | Recovered/resolved | Not Applicable | Unrelated | 1 |

- **Diff Folder:** If a data record is new or deleted, it impacts the whole record. So the whole record will colored. This process is relatively easy to achieve. However, if a data record is updated and only a few variables/fields are updated, coloring these variables/fields from the rest of non-changed fields is quite challenging.

In order to achieve this, we need to have another folder. This folder will identify all individual fields that are updated. For example:

F:\Project1\Study999_100\Datasets \Diff\

The **data structure** of these datasets is as follows. It is an output from PROC COMPARE. It is used to identify base (Benchmark Dataset), compare (Current Dataset), and differences

(DIFF). This dataset is used to color specific fields that have been updated. The example below shows the same AE (Rhinorrhea) is coded to a new HLGT.

| VIEWTABLE: Crodatau.Ae_updated_paper | | | | | | | |
|--------------------------------------|---------------------|--------------------|----------------------------|----------------|---------------|--------------------------------------|------------------------|
| | Type of Observation | Observation Number | Subject name or identifier | eCRF page name | Adverse Event | Adverse EventHLGT | Adverse EventHLGT_CODE |
| 1 | BASE | 9 | AAAAA | Adverse Events | Rhinorrhea | | |
| 2 | COMPARE | 9 | AAAAA | Adverse Events | Rhinorrhea | Respiratory tract signs and symptoms | 10079101 |
| 3 | DIF | 9 | AAAAA | | | XXXXXXXXXXXXXXXXXXXXXXXXXXXX | |

4. PROCESS

- Define Benchmark Folder: Can be any datacut folder
- Define Current Folder: Can be any folder which will be compared with Benchmark Folder
- Compare datasets in the current folder with that in the benchmark folder. This is achieved by a macro:

```
%find_ds_difference_rave (dsin=AE, order_by= %str(Subject, RecordId), idstm=%str(Subject RecordId));
```

This macro will

- Identify any new records
 - Identify any deleted records
 - Identify any updated records. Then use PROC COMPARE to identify what variables are updated
 - Combine new/updated/deleted/un-changed records together and output the datasets to the COMPARE folder
 - Output PROC COMPARE output to DIFF folder
- Generate colored data listings/Patient profiles. This is achieved by a macro:

```
%dataset_difference_color (dsin=AE, order_by= %str(Subject, RecordId), idstm=%str(Subject RecordId));
```

This macro will do:

- If a record is new, color the whole record **green** with PROC REPORT style formatting
- If a record is deleted, color the whole record **grey** with PROC REPORT style formatting

- If a record is updated, go through each variable and color the updated variable **pink** with PROC REPORT style formatting. This step will need to use the datasets in the DIFF folder. This is the most challenging step.
- If a record is not changed, output it without any formatting.

5. DISCUSSIONS

Data review is always a tedious process for Medical Monitors, Biostat, and CDM, especially when one is responsible for multiple studies. Yet, data review is a critical part in clinical trials. Data review meetings are routinely scheduled in the life cycle of clinical trials. Data listings, patient profiles, CSRs are usually cumulative. However, data reviewers do not like to review the same data they had reviewed before. Rather, they prefer to review data incrementally. That is to review any new/updated/deleted data. Certainly, they also want to see the whole data whenever needed.

Color data listing discussed here is a solution to the challenge. We create data listings, patient profiles with complete datasets as usual. But we go one more step to color any new/updated/deleted data in the listings. So it is very easy for data reviewers to know what data need more attention.

Though we usually use the first datacut as benchmark, it can be changed to any subsequent datacut as needed. Furthermore, we can use this process to identify any data differences between data transfers, patient profiles.

So far, we only implemented this on data listings and patient profiles. But if people are curious to know any data differences between different versions of CSRs, DSURs, this process can be used to color-code these reports as well.

After we implemented this process, we got overwhelming positive feedback from data reviewers. It usually takes them a couple of weeks to finish whole data reports review. Now they can finish the data review in a couple of days.

6. Sample Output

6.1. Sample Color Data Listings

| | A | B | G | J | Q | U | X | Y | AB | AC |
|-----|--------------------------------------|---------|----------------|---|----------------------------|-------------|-------------|----------------------------|------------------|------------------|
| | Benchmark | Subject | eCRF Page | Adverse Event | Adverse EventPT | Start Date | End Date | Outcome | Action Taken | Relationship |
| 1 | | CCCCC | Adverse Events | Mechanical Fall | Fall | 16 Feb 2019 | 16 Feb 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 90 | Updated after snapshot on 07OCT12019 | CCCCC | Adverse Events | Contact dermatitis right wrist | Dermatitis contact | 03 Sep 2019 | 03 Oct 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 91 | | CCCCC | Adverse Events | Urinary frequency | Pollakiuria | 24 Jun 2019 | | Recovering/resolving | Dose Not Changed | Possibly Related |
| 102 | Deleted after snapshot on 07OCT12019 | DDDDD | Adverse Events | Possible pelvic tumour (most likely benign). No further information available | | 28 Feb 2019 | | Not recovered/not resolved | Not Applicable | Unrelated |
| 103 | | EEEEEE | Adverse Events | Mechanical fall | Fall | 27 Jul 2019 | 27 Jul 2019 | Recovered/resolved | Dose Not Changed | Unrelated |
| 104 | | EEEEEE | Adverse Events | Mechanical fall | Fall | 26 Aug 2019 | 26 Aug 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 105 | New after snapshot on 07OCT12019 | EEEEEE | Adverse Events | Diabetes | Diabetes mellitus | 12 Oct 2019 | 7 Nov 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 106 | New after snapshot on 07OCT12019 | EEEEEE | Adverse Events | Redness in foot secondary to insect bite | Arthropod bite | 1 Oct 2019 | 8 Oct 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 107 | | MMMMM | Adverse Events | Nausea | Nausea | 28 Nov 2018 | 28 Nov 2018 | Recovered/resolved | Not Applicable | Unrelated |
| 114 | | NNNNNN | Adverse Events | Post-infusion weakness | Asthenia | 01 May 2019 | 02 May 2019 | Recovered/resolved | Dose Not Changed | Related |
| 115 | Updated after snapshot on 07OCT12019 | FFFFFF | Adverse Events | Worsening weakness | Asthenia | 23 May 2019 | 20 Oct 2019 | Not recovered/not resolved | Not Applicable | Unrelated |
| 116 | Updated after snapshot on 07OCT12019 | FFFFFF | Adverse Events | MS relapse | Multiple sclerosis relapse | 15 Jul 2019 | 25 Sep 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 117 | New after snapshot on 07OCT12019 | FFFFFF | Adverse Events | Worsening of existing neurological symptoms | | 16 Dec 2019 | | Not recovered/not resolved | Not Applicable | Unrelated |
| 118 | | QQQQQ | Adverse Events | Common cold | Nasopharyngitis | 24 Aug 2019 | 09 Sep 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 119 | | QQQQQ | Adverse Events | Chest pain (musculoskeletal) | Musculoskeletal chest pain | 30 Aug 2019 | 09 Sep 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 120 | New after snapshot on 07OCT12019 | GGGGG | Adverse Events | Acute Bronchitis | Bronchitis | 28 Oct 2019 | 01 Nov 2019 | Recovered/resolved | Not Applicable | Unrelated |
| 121 | | GGGGG | Adverse Events | Sweating | Hyperhidrosis | 15 Jan 2019 | | Not recovered/not resolved | Dose Not Changed | Unrelated |
| 122 | | GGGGG | Adverse Events | Sunburn | Sunburn | 26 Jan 2019 | 02 Feb 2019 | Recovered/resolved | Not Applicable | Unrelated |

6.2. Sample Color Patient Profile

Patient: Subject XXXXX

Page 7 of 59

Concomitant Medications

| Benchmark | Seq | Days After First Dose | Medication | ATC | Indication | Route | Start Date | End Date | Dose | Unit |
|--------------------------------------|-----|-----------------------|--|---------------------------------|--------------------------------------|-------|-------------|-------------|------|-------|
| | 1 | -277 | Ampyra | NERVOUS SYSTEM | Multiple Sclerosis, Gait Disturbance | Oral | 16 AUG 2018 | Yes | 10 | mg |
| | 2 | -1622 | cholecalciferol, vitamin D3, (VITAMIN D3) | ALIMENTARY TRACT AND METABOLISM | vitamin D deficiency | Oral | 10 DEC 2014 | Yes | 2000 | IU |
| | 3 | -2296 | baclofen | MUSCULO-SKELETAL SYSTEM | Multiple Sclerosis, spasticity | Oral | 04 FEB 2013 | Yes | 10 | mg |
| | 4 | -1069 | CALCIUM CITRATE ORAL | ALIMENTARY TRACT AND METABOLISM | supplement | Oral | 15 JUN 2016 | Yes | 1 | tab |
| Updated after snapshot on 07OCT12019 | 5 | -2257 | OCUVITE eye + multi (Lutein, Zeaxanthin, daily multivitamin) | SENSORY ORGANS | Visual Loss | Oral | 15 MAR 2013 | Yes | 1 | tab |
| | 7 | -2041 | fluoxetine | NERVOUS SYSTEM | Depression | Oral | 17 OCT 2013 | 24 Feb 2014 | 10 | mg |
| | 8 | -1911 | fluoxetine | NERVOUS SYSTEM | depression | Oral | 24 FEB 2014 | 27 Aug 2014 | 20 | mg |
| | 9 | -1727 | fluoxetine | NERVOUS SYSTEM | depression | Oral | 27 AUG 2014 | 12 Jan 2015 | 10 | mg |
| | 10 | -1589 | fluoxetine | NERVOUS SYSTEM | depression | Oral | 12 JAN 2015 | 08 Jul 2015 | 20 | mg |
| | 11 | -1412 | fluoxetine | NERVOUS SYSTEM | depression | Oral | 08 JUL 2015 | 09 Jun 2016 | 10 | mg |
| | 12 | -2386 | fluoxetine | NERVOUS SYSTEM | depression | Oral | 06 NOV 2012 | 17 Oct 2013 | 20 | mg |
| | 13 | -2282 | cyanocobalamin (vitamin b-12) | BLOOD AND BLOOD FORMING ORGANS | supplement | Oral | 18 FEB 2013 | Yes | 500 | mcg |
| | 14 | -44 | collagen | MUSCULO-SKELETAL SYSTEM | supplement | Oral | 06 APR 2019 | Yes | 1 | scoop |
| | 15 | -277 | dalfampridine | NERVOUS SYSTEM | Multiple Sclerosis | Oral | 16 AUG 2018 | Yes | 10 | mg |
| | 16 | -2299 | Ascorbic Acid | ALIMENTARY TRACT AND METABOLISM | Supplement | Oral | 01 FEB 2013 | 07 Feb 2013 | 500 | mg |
| Updated after snapshot on 07OCT12019 | 17 | -236 | levocetirizine | RESPIRATORY SYSTEM | rhinitis | Oral | 26 SEP 2018 | Yes | 5 | mg |
| New after snapshot on 07OCT12019 | 18 | -431 | acetaminophen | NERVOUS SYSTEM | Prophylactic antipyretic | Oral | 15 MAR 2018 | 15 Mar 2018 | 1000 | mg |

7. CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the authors at:

Author Name: Charley Z. Wu

E-mail: charleyzwu@yahoo.com

SAS® and all other SAS® Institute Inc. product or service names are registered trademarks or trademarks of SAS® Institute Inc. in the USA and other countries. ® indicates USA registration.

Other brand and product names are trademarks of their respective companies.